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Tolerance and Safety of Pharmacologic Coronary Vasodilation With
Adenosine in Association With Thallium-201 Scintigraphy in Patients
With Suspected Coronary Artery Disease
ANA ABREU, MD, JOHN J. MAHMARIAN, MD, SHIGEYUKI NISHIMURA, MD,
TERRI M . BOYCE, BS, CNMT, MARIO S . VERANI, MD, FACC
Houston, Texas
Adenosine thallium-201 myocardial scintigraphy is a promising
test for coronary artery disease detection, but ifs safety has not
been reported In large patient cohorts. Accordingly, the tolerance
and safety profile of adenosine infusion were analyzed in 607
patients (351 men, 256 women, mean age 63 :t 11 years) under-
going this test either because of suspected coronary artery disease
(Group 1, n = 482) or for risk stratification early (5,2 :t 2,8 days)
after myocardial infarction (Group 11, n = 125) . Adenosine
increased the heart rate from 74.5
f
14.0 to 91 .8 a 15 .9 beats/min
(p < 0 .001) and decreased systolic blood pressure
from 137.8 a
26.8 to 120.7 t 26.1 mm He (p < 0.001). Side effects were
frequent and similar in both groups . Flushing occurred in 35%,
chest pain in 34%, headache in 21% and dyspnea in 19% of
patients . Only 35 .6% of Group I patients with chest pain during
adenosine infusion had concomitant transient perfusion abnor-
Many patients with suspected coronary artery disease in
whom stress thallium-201 scintigraphy would be desirable
are unable to perform an exercise test because of a variety of
physical ailments. 1n addition, many other patients referred
for exercise thallium scintigraphy fail to achieve an adequate
exercise test because of the effects of anti-ischemic drug
therapy or because of poor physical conditioning . In such
patients dipyridamole has been widely and successfully used
as an alternative to exercise in conjunction with thallium
imaging (1-9).
Although dipyridamole has had a good safety
record in large numbers of patients (8-12), its side effects are
frequent, often require the administration of aminophylline
and occasionally are life threatening (11-16).
Recently our group (171 introduced thallium-201 scintig-
raphy with pharmacologic vasodilation using adenosine in-
stead of dipyridamole for the diagnosis of coronary artery
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malittes, compared with 60
.7% of Group 11 patients (p < 0.05) .
First- and second-degree AV block occurred in 9 .6% and 3,6% of
patients, respectively, and ischenic ST changes in 12 .5% of cases.
Concomitance of chest pain and ischemic ST depression was
uncommon (6%) but, when present, predicted perfusion abnor-
malities in 73% of patients .
Most side effects ceased rapidly after stopping the adenosine
infusion . The side effects were severe in only 1
.6% of patients and
in only six patients (1%) was it necessary to discontinue the
infusion . No serious adverse reactions such as acute myocardial
infarction or death occurred. These data attest to the excellent
safety of adenosine infusion as an adjunct to thallium-201 selntig .
raphy in humans even within a few days of acute myocardial
infarction .
(J Am Coll Cordial 1991;18:730-S)
disease
. The values for sensitivity and specificity (83% and
94%p, respectively) were comparable with those previously
reported from our laboratory with thallium-201 tomography
after either dipyridamole administration (18) or treadmill
exercise (19).
Side effects were frequent with adenosine but
transient because of the drug's extremely short biologic
half-life (2 to 10 s) (20,21) and did not require aminophylline
administration .
The short half-life of adenosine and the ability to regulate its
infusion rate are essential attributes for achieving controlled
pharmacologic coronary vasodilation . However, adenosine is a
very potent arteriolar vasodilator that may cause myocardial
ischemia through a coronary steal phenomenon (22) . In addi-
tion, the drug decreases atrioventriculnr (AV) node conduction
velocity, as evidenced by its efficacy in treating reentrant
supravemricular tachycardia (23-25). Thus, the safety of aden-
osine must be established in a huge cohort of patients with a
wide spectrum of coronary artery disease before the drug can
be generally recommended .
Methods
In this study we report in detail the tolerance and safety
of intravenously infused adenosine in a large cohort of 607
0735-1097191153 .50
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subjects that included 125 patients studied for risk stratifi-
cation early after an acute myocardial infarction .
Study patients. From May 25, 1988 until March 14 . 1990,
607 consecutive patients (351 men
. 256 women, mean age
[3 SD] 63
.
I I years, range 31 to 89) underwent adenosine
thallium-201 imaging in our laboratory . The research proto-
col was approved by the Institutional Review Board for
Human Research at both Baylor College of Medicine and
The Methodist Hospital . All patients signed informed con-
sent.
The patient cohort consisted of 482 patients (255 men and
227 women) without evidence of acute myocardial infarction
(Group 1) and 125 patients (96 men and 29 women) with
recent myocardial infarction (Group II)
. The adenosine
thallium-201 scintigrams were performed early (5 .2 ± 2.8
days) after myocardial infarction in Group 11 patients . Most
Group I patients were referred for pharmacologic stress
testing primarily because they could not perform an ade-
quate exercise test because of physical impediments such as
arthritis, claudication, stroke, amputation, gross obesity and
poor physical conditioning
. A small fraction of these patients
was previously included in our initial report on adenosine
thallium scintigraphy
(17).
Specific indications for the test were as follows : risk
stratification after acute myocardial infarction (23.259) ;
screening for coronary artery disease (19
.6%) ; assessment of
patients with stable angina (17%) ; evaluation after coronary
artery bypass graft surgery (10%) or percutaneous translum-
inal coronary angioplasty (8%) ; assessment of atypical chest
pain (8%) ; preoperative cardiac risk evaluation in patients
scheduled to undergo peripheral vascular surgery (7 .2%) and
assessment of the functional significance of coronary artery
stenoses (6.4%) .
The 407 patients (67.1%) who were taking antianginal
medications at the time of tomographic imaging included 291
(60
.4%) Group I and 116 (93%) Group Il patients . Of the
entire study population, 237 patients (39%) were taking
nitrates, 125 (20 .6%) were taking a beta-adrenergic blocking
agent and 293 (48.3%) were taking a calcium channel antag-
onist
. Whenever possible, these medications were withheld
the morning of the test .
Exclusion criteria were as follows:
hypotension (systolic
blood pressure <90 mm Hg)
; a history of asthma or severe
chronic obstructive pulmonary disease requiring broncho-
dilators or steroids
; wheezing immediately before the test ;
severe congestive heart failure (New York Heart Associa-
tion class G1 or IV) ; second or third degree atrioventricular
(AV) block; use of dipyridamole or theophylline within 24 h
and use of caffeine within 12 h of the test . Scintigraphy was
performed after patients had fasted for at least 12 h .
Adenosine administration, Adenosine (Adenoscan) was
infused into an antecubital vein with use of a microproces-
sor-controlled pump (volumetric infusion pump FLO-GARD
8000), whereas thallium-201 was always injected as a bolus
into a contralateral vein and flushed with 10 ml of normal
saline solution . To prevent a bolus infusion of adenosine
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during the thallium-201 injection and flush . adenosine and
thallium-201 were never administered into the same vein .
In the first 137 patients without recent myocardial infarc-
tion- we assessed the safety of adenosine by performing
I min dose titrations at infusion rates of 50 . 75 . 100 and
140
µg!kg
per min . Thallium-201 (3 mCi) was injected aft"r
I min at this highest dose and the adenosine infusion was
maintained for an additional 3 min. Once we were satisfied
with the safety profile of these doses . the test was performed
in the subsequent patients at a constant infusion rate of
140 yglkg per min over 6 min . The same dose of thallium-201
was injected at 3 min and the infusion maintained for an
additional 3 min. Patients with recent myocardial infarction,
however, were always given a stepwise infusion. Tonto-
graphic imaging was performed commencing within 10 min
of the thallium injection, as previously reported from our
laboratory (17).
The patients were observed continuously throughout the
study by a cardiology fellow, a registered nurse and technol-
ogists in nuclear medicine and electrocardiography (ECG)
.
The systemic blood pressure and a 12-lead ECG were
recorded before, at every minute during and for at least
10 min after the infusion of adenosine . The personnel in
attendance continuously monitored any symptoms during
the adenosine infusion .
Statistical analysis. Paired r tests and the Wilcoxon
signed rank test were used to analyze variables with and
without a normal distribution
. respectively . The chi-square
test was used to compare categoric variables. A p value <
0.05 was considered significant
. Data are expressed as mean
values ' SD
.
Results
Hemodynamic Effects of Adenosine (Table 1)
Heart rate. The mean baseline heart rate for the total
group increased significantly during the adenosine infusion .
An increase in heart rate was observed in 569 patients
(93 .7%), but 21 patients (3 .5%) had no change and 17 (2 .8%)
had a decrease in heart rate
. The percent of patients with an
increase, a decrease or no change in heart rate was similar in
Groups I and II .
Systolic blood pressure. For the total study population
and in Groups I and 11, the systolic blood pressure fell
significantly, albeit modestly
. Systolic blood pressure de-
creased in 515 patients (84.8%), remained unchanged in 16
(2 .6%) and paradoxically increased in 76 (12.6%)
. The sys-
tolic pressure decreased transiently to <80 n
..~ Hg in 15
patients (2
.5%) . The percent of patients with a decrease, an
increase or no change in systolic blood pressure was similar
in Groups I and II.
Diastolic blood pressure. The diastolic blood pressure
decreased significantly during adenusine infusion
. It de-
creased in 483 patients (79.6%) but did not change in 50
(8.2%) and increased in 74 (12 .2'0
. Both Group I and II
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Table 1 . Hemodynamie Changes During Adenosine Infusion
patients had a comparable, significant decrease in diastolic
pressure during adenosine infusion
.
Electrocardiographic Alterations
ECG intervals (Table 2). The PR interval increased sig-
nificantly in both Group I and II patients, but QRS and QT
intervals did P.ot change significantly in either group .
AV block. During the adenosine inftsion, 58 patients
(9.6%) (9.8% in Group I and 8 .8% in Group Il) developed
first-degree AV block that consistently started within the Ist
5 min (mean 1 .8 ± 0.91 and always resolved within 2 min
after discontinuation of the infusion.
Second-degree AV block occurred in 22 patients (3 .6%)
(3 .7% in Group I and 3
.2% in Group 1I, p = NS). Further-
more, second-degree AV block occurred in 15 (25 .9%) of the
58 patients with adenosine-induced first-decree AV block .
Mobitz type I and 2 :1 AV block occurred in 18 and 4
patients, respectively. Second-degree AV block began at a
mean time of 1 .9 ---- 1 .1 min after the start of the infusion, was
Table 2 . Electrocardiographic Interval Changes With
Adenosine Ims)
Graups I and II are defined in Table I .
Group I Group II
Total Patients In = 4821 (n = 1251
Group I = patients with suspected coronary artery disease ; Group 11 = patients undergoing risk stratification
after an acute myocardial infarction .
often fleeting and disappeared within 2 min of discontinua-
tion of the infusion .
Second-degree AV block with a slow ventricular rate (46
beatslmin) occurred in two patients but promptly resolved
after the adenosine infusion was reduced.
The incidence of second-degree AV block was 4 .9% (17 of
345 patients, all in Group 1) with the fixed dose, compared
with 1 .9% (5 of 262 patients) with the stepwise infusion
method (p < 0.05) . With the latter infusion method, patients
with acute infarction were somewhat more likely to have
second-degree AV block (4 [3.2%] of 125 patients) than were
those without infarction (1 [0 .7%] of 137 patients), but the
difference was not statistically significant (p > 0 .05) . No
patient in this series developed third-degree AV block .
ST segment depression . Significant ST segment depres-
sion (>1 mm measured at 80 ms after the l point) occurred in
76 (12 .5%) of the 607 patients during the adenosine infusion
at a mean time of 2 .7 t 1 .4 min . In patients with ST
depression, chest pain occurred with a similar frequency
(p = NS) among Group I and Group 11 patients (50.8% and
41 .2%, respectively) .
The majority of patients (55 [72 .4%] of 76) with significant
ST segment depression had a thallium-201 perfusion defect ;
it occurred in 38 (64.4%) of the 59 Group I and in all 17
Group 11 patients . Reversible (partially or totally) perfusion
defects were observed in 59 .3% of Group I and 58
.8% of
Group 1I patients with ST segment depression .
Side Effects (Table 3)
The majority of patients (79.2%) had at least one symp-
tom during the infusion, which occurred in 278 (80 .6%) of
345 patients during the fixed dose and in 203 (77.5%) of 262
during the stepwise dose infusion (p = NS) . With the
exception of chest pain, symptoms occurred with similar
frequency among Group I and Group 11 patients .
Chest pain. Chest pain occurred frequently (33 .8%) and
was reported as mild or moderate in the majority of patients .
Hear rale Ibeatslmm)
Baseline
74.5 t 14.0 74.1 z 13.9 76.2 0 14.6
Adenosine 91.8 * 15.9 91 .8 t 15.9 91 .9 *_ 16.1
p value <0.001 <0 .001 <0.001
Systolic blood pressure Imm Hg)
Baseline 142
.4 t 26 .7 120.2 a 19 .1
137.8 *- 26
.8
Adeeor,ee 120.7 *_ 26.1 124.6 t 26 .6 107.6 ± 19 .7
p Value <0.001 <0 .001 <0 .001
Diastolic
blood pressure Imm Hg)
Baseline 79.5 x 11 .7 74.0 t 10 .978.2 *_ 11 .8
Adenosine 67.5 t 13.1
68.1 x 13
.6 65.6 t 11 .4
p Value
<0.001 <0 .001 <0 .901
Total Patients Grasp I Group II
PR interval
Baseline
175 t 31 176 '- 32 168 `- 29
Adenosine 184 t 38 187 t 40 175 t 32
p value <0 .001
<0 .001 <0 .001
QRS duration
Baseline 89 t 21 89 t 20 90 -_ 26
Adenosine 92 z 34 92 a 36 91 t 28
p value >0.05 >0 .05
>0 .05
QT duration
Baseline 381 t 52 384 A 51 366 * 51
Adenosine 379 m 51 382 5 50 370 < 52
p value
>0 .05 >0.05 >0.05
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Table 3. Side Effects During Adenosine Infusion
Groups I and 11 are defined in fable 1 .
The pain was typical of angina in only 37% of patients . In the
remainder the pain was sharp or "stabbing -" in quality .
lasting only a few seconds a .:d was located usually under the
left nipple or subcostaliy . Chest pain was more frequent (p <
0.05) in Group 1 (36 .7%) than Group 11 patients (22 .4%),
although its frequency was not significantly different among
patients receiving the stepwise or constant infusion methods
(36.3% vs . 31 .9%, respectively) . Chest pain started at 2
.5
1 .9 min (range 0
.5 to 6) after the adenosine infusion started .
Only 37 (18%) of 205 patients with chest pain had ST
segment depression, which occurred in 30 (16
.9%) of 177
Group I and 7 (25%) of 28 Group II patients (p = NS)
.
Chest pain versus perfusion abnormalities
. Perfusion ab-
normalities by thallium-201 tomography occurred in 99 pa-
tients (48
.3%) with chest pain-72 (40.71) of 177 Group I
and 27 (96.4%) of 28 Group 11 patients
. Totally or partially
reversible perfusion defects in patients with chest pain
occurred in 35 .6% of Group 1 and 60.7% of Group 11 patients
(p < 0
.05)
. Perfusion abnormalities occurred in 220 patients
(54.7%) without chest pain-126 (41%) of 305 Group I and 94
(96.9%) of 97 Group 11 patients
. Patients with concomitant
chest pain and significant ST segment depression In = 371
had a high frequency of perfusion defects (73%) . with most
(81 .5%) showing redistribution .
Clinically Important Side Effects
Severe chest pain . Ten patients (1 .6%), eight in Group I
and two in Group 11, had what we considered a "clinically
important" side effect
. Six of these patients. four in Group I
and two in Group 11 . had severe chest pain that was
controlled by either discontinuing the adenosine infusion
(n = 4) or reducing the infusion rate In = 2)
. These patients
naSEU FT 5L .
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also received either sublingual niuoelycerin In = 41 or
intravenous aminophylline (75 to 150 mg . n - 3) .
Hrpotcrrsion . inree additional Group I patients devel-
oped a systolic blood pressure <80 mm Hg and dizziness .
This .vas corrected within I min by either adjustment of the
adenosine dosage In = 21 or premature terminacon of the
infusion In -
1) .
Dyspnea and bronchospasm
. One patient in Group I had
dyspnea and bronchospasm 30 s after the start of the
adenosine infusion, which resolved completely after termi-
nation of the infusion and administration of aminophylline .
Discussion
This study reports the safety of intravenously infused
adenosine in a large consecutive patient population referred
for evaluation of coronary artery disease. Our data empha-
size that adenosine is well tolerated and safe when used as an
adjunct to diagnostic myocardial perfusion imaging . The
m- in advantage of adenosire over dipyridamole is its ex-
tremely short plasma haliife (2 to 10 s) 125 .21), which
accounts for the rapid cessation of side effects when admin-
ister tion of the drug is stopped . In addition, the dose can he
increased or decreased rapidly. if necessary .
Side effects of adenosine and dipyridamole. Most of the
side effects produced by adenosie a can be explained by its
potent vasodilator action
. Despite a somewhat higher fre-
quency of side effects with adenosine compared with dipyr-
idamole (8-12),
they were of short duration and well toler-
ated by nearly all patients, irrespective of the infusion
method (stepwise or fixed dose) . A very recent study (II)
analyzed the safety of intravenous dipyridamole thrllium-
201 scintigraphy in 3,911 patients studied at 64 clinical sites
for several years . The investigators report fewer side effects
with dipyridamole than those observed in earlier studies by
other investigators (1 .4.9, 10). Higher doses of dipyridamole,
however. may cause more frequent side effects (26) by
further increasing the blood and tissue adenosine levels
.
The frequency of chest pain in our patients was somewhat
higher 33 .8%) than that reported by Homms et at
. (10)
during dipyridamole infusion (26%) . although the reported
frequency of this symptom with dipyridamole varies widely
(18r% to 42'7) (9). Patients with chest pain and concomitant
ST segment depression had a higher frequency of perfusion
defects than did those with chest pain alone (73% vs
. 48 .3%) .
Furthermore, the majority (59
.5%) of patients with chest
pain and ST depression had thallium-201 redistribution.
Mechanism of adenosine-induced chest pain
. The mecha-
nism whereby adenosine induces chest pain is still unknown
.
Adenosine may cause anginal pain in patients with coronary
artery disease (27),
but healthy volunteers also commonly
develop chest pain when given high doses of the drug
(28)
.
The mechanism of dipyridamole-induced chest pain is also
still unclear and, even when the pain is accom7anied by ST
depression, the severity or extent of coronary artery disease
cannot he reliably predicted (29) .
Overall, significant ST
Total l71
(n
= 607)
Group 1
171
In
= 4821
Group II
(`7.1
In = 1251 p Value
Fond flushing 34 .8 34 376 NS
Chest pain 33 .8 76 .7 22 .4 <0.05
Headache 20 .6 21 .5 16 NS
Dysprs n
Throat pain
18 .8
91
17 .8
10.4
22.4
i6
IN
NS
Elpilintric pain
9.4
10
T2 14S
Nausea 5.1 62 0 .5 VS
Warm feeling 4.8 5.2 3 .2 NS
Dirtiness 4.8 3.7 8 .8 N5
Nsekpain 4 .6 4.2 6A NS
Sourtavc 2 .8 2.7 -- NS
Jaw pain 2 .1 1 .6
N5
Am pain 2 .3 0.8 NS
Light-headedness 1 .2 4 NS
Shoulder pain L7 L5
2 a NS
Pressure in cars 1 0 .8
1 .6
NS
Any symptom 79.2 80.6 77 .5 N5
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segment depression occurred in 12.5% of the patients, with a
similar distribution among those with and without acute
infarction . This is in the range reported with dipyridamole
(6% to 21%) in different series (9) . Patients without demon-
strable coronary artery disease often develop chert pain
during dipyridamole administration (29).
Mechanism of
adenosine-induced
dyspnea. Dys?nea oc-
curred in 18 .8% of our patient cohort but was usually mild
and ended promptly after the infusion was discontinued .
Dyspnea during adenosine administration can be attributed
to stimulation of the carotid chemoreceptors, which leads to
hyperventilation due to an increase in respiratory rate and
depth (30). Only I of our 607 patients had bronchospasm,
which responded promptly to discontinuation of adenosine
and administration of aminophylline . Adenosine has been
reported to provoke bronchospasm when administered as an
aerosol to patients with asthma (3t1
. Severe bronchospasm
followed I,y respiratory arrest has been rarely described with
dipyridamole (10) .
More serious complications . In our experience it, date,
adenosine has not caused myocardial infarction, cardiac or
respiratory arrest or death . Furthermore, the most severe
symptoms experienced by our patients were easily con-
rolled with either dosage adjustments or termination of the
infusion
. Only a few patients required additional therapy
with nitroglycerin or aminophylline. However, dipyridamole
may very rarely cause fatal and nonfatal myocardial infarc-
lion (I1), ventricular fibrillation (13) and severe broncho-
spasm followed by respiratory arrest (10). Although these
more serious complications are unlikely to occur with aden-
osine because of its remarkably short half-life, patients must
be selected and monitored carefully for this test because
myocardial ischemia does occur in some patients and thus
there is a potential for serious side effects .
AV block during adenosine infusion
. Mobitz type I or 2:1
second-degree AV block occurred in relatively few patients
and was preceded by first-degree AV block in the majority
(68 .2%) of patients
. Subjects with and without acute infarc-
tion had a similar frequency of second-degree block, al-
though the latter was slightly more common in patients who
received a fixed dose infusion . Adenosine-induced AV block
is due to this drug's well recognized decrease of the conduc
tion velocity in the upper portions of the AV node
(32) .
How much adenosine is enough? In view of the high
frequency of side effects-even though they were transient
and generally well tolerated-one might question whether
the adenosine doses we used could be reduced without loss
of drug efficacy . In fact, Wilson et al
. (33) demonstrated a
mean increase in coronary blood flow velocity of 3 .1- and
4
.4-fold with intravenous adenosine doses of 70 and
100 aaglkg per min, respectively .
Because the myocardial extraction fraction of thallium-
201 decreases during hyperemia (34),
it is reasonable to
assume that any increase in coronary blood flow beyond a
factor of 3 will not result in greater myocardial thallium
extraction
. Hence, a lower dose of adenosine may conceiv-
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ably be as efficacious as the high doses we used . However,
there are four reasons why we have continued to use a high
dose infusion (17) : I) It is likely that at lower doses some
patients will have inadequate coronary vasodilation (33) ; 2)
at adenosine doses <140 ftglkg per min, the coronary blood
flow may increase cyclically rather than continuously (33) :
and 3) there is considerable variability in the amount of
adenosine that may reach the coronary circulation from a
peripheral venous infusion site because of the very short
plasma half-life of adenosine and avid uptake by the red
blood cells. Finally, the doses we now use are safe, well
tolerated in the great majority of patients and detect coro-
nary artery disease with a high sensitivity and specificity
when combined with thallium-201 single-photon emission
computed tomography (17) . Other groups (35,36) have re-
cently reported that at a dose of 140 µg/kg per min adenosine
is safe and detects coronary artery disease with high sensi-
tivity and specificity when coupled with tomographic thal-
lium imaging .
Limitations of adenosine thallium scintigraphy . There are
several limitations of adenosine thallium scintigraphy, I) Con-
trary to exercise scintigraphy, it does not allow assessment of
the exercise performance, which is prognostically important .
2) During intense coronary hyperemia with either adenosine or
dipyridamole, the extraction fraction of thallium-201 decreases
considerably relative to the increase in flow, a limitation that
.
thus far, does not appear to compromise the sensitivity of the
test . 3) Adenosine and dipyridamole may be potentially harm-
ful to patients with bronchospasm and ineffective in patients
who use methylxanthines . Finally, the cost of a 6 min adeno-
sine infusion would be high if extrapolated from the cost of a
single vial of the commercially available product (Adenocard)
used for treating cardiac arrhythinias . However, it is expected
that the cost of adenosine prepackaged for use with cardiac
scintigraphy will he lower than the sum of the cost of the
individual vials
. A true cost analysis comparing adenosine and
dipyridamole is not yet possible because the former does not
have a market price but, in all likelihood, the cost of the two
agents will be comparable.
Conclusions. Despite a high frequency of side effects with
adenosine, most were mild and of very short duration. The
rare instances of severe untoward effects were rapidly con-
trolled by decreasing the rate of the infusion or, in extreme
cases, by discontinuing it . Although additional therapy is
usually not required, the side effects do respond promptly to
small intravenous doses of aminophylline, an adenosine
receptor blacker.
Adenosine can be used safely in patients with or without
recent myocardial infarction . In this large series of patients
from a single institution, adenosine administration was
shown to be safe at a constant infusion rate of 140 µg/kg per
min. However, to ensure the safety of patients considered to
be at high risk (for example, those with recent myocardial
infarction, unstable angina, borderline hypotension, sinus
bradycardia, questionable history of bronchospasml . we
]ACC Vol . I8, No. 3
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continue Lo, recommend a stepwise infusion of adenosine in
this group .
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